← Eichor
Condition: Multiple Myeloma Relapsed Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Multiple Myeloma Relapsed

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07454382In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirector
Phase N/A · 68 location(s) · Janssen-Cilag Ltd. · NCT06285318A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07493135A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07359014Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT04271644Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
NA · 2 location(s) · Pack Health · NCT05053607Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Alfred Chung, MD · NCT06348108Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Ag
Phase 1 · 27 location(s) · AbbVie · NCT06896916Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05363111A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments
Phase 1/Phase 2 · 17 location(s) · Bristol-Myers Squibb · NCT05372354A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administrati
Phase 2 · 1 location(s) · Janssen Research & Development, LLC · NCT07589634Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · University of Chicago · NCT05789303Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4 · 1 location(s) · University Health Network, Toronto · NCT06251076Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Hangzhou Sumgen Biotech Co., Ltd. · NCT07454187Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05565807A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07609030CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · 266 location(s) · Celgene · NCT05519085
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.